Press release

Medios AG: Strong operating cash flow – record figures as expected also for revenue and earnings in the third quarter of 2023

Financials Q3 2023 vs. Q3 2022:

• Revenue up 16.9% to €489.9 million
• EBITDA pre¹ up 12.2% to €17.2 million

Berlin, October 24, 2023 – Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, again grew strongly in the third quarter of 2023, as expected. Based on preliminary and unaudited figures (IFRS), revenue in the third quarter amounted to around €489.9 million (+16.9% vs. Q3 2022) and EBITDA pre¹ to around €17.2 million (+12.2% vs. Q3 2022). These figures are slightly above the current analyst consensus for Q3 2023 (revenue: €455.4 million; EBITDA pre¹: €16.0 million). Cash flow from operating activities amounted to €86.0 million in the third quarter (previous year: €7.9 million) resulting from the sale of inventories strategically built up in the first half of the year.

In the period from January to September 2023, revenue increased by 10.9% to €1,343.5 million (previous year: €1,211.4 million) according to preliminary figures. Medios achieved a preliminary EBITDA pre¹ increase of 5.5% to €46.3 million (previous year: €43.8 million) in the same period. These figures are also slightly above the current analyst consensus for the nine-month period 2023 (revenue: €1,308.7 million; EBITDA pre¹: €45.0 million).

Matthias Gaertner, CEO of Medios AG: "We proudly look back on the best quarter in the history of Medios AG so far – with a high increase in revenue, a significant increase in earnings and a particularly strong operating cash flow. I am very pleased that together as a team we were once again able to achieve such great success – and this in these generally challenging times.”

Medios will publish the full Quarterly Statement as of September 30, 2023, on November 14, 2023.

Important dates for Medios AG in the 2023 financial year:

November 14: Quarterly Statement (Q3 and 9M 2023)

November 30: CIC Market Solutions Forum – Paris

December 06: Berenberg European Conference – Pennyhill

-------------------

About Medios AG

Medios AG is the leading provider of Specialty Pharma Solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies.

Medios AG is Germany's first listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).

www.medios.ag

Contact
Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
c.nickolaus@medios.ag
www.medios.ag

Anna Höffken
Senior Consultant Investor & Public Relations
Kirchhoff Consult AG
Borselstraße 20 | 22765 Hamburg
T +49 40 609 186 34
anna.hoeffken@kirchhoff.de
www.kirchhoff.de

Disclaimer

This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing.